by John A. Jenkins | Nov 6, 2024 | FDA, FOIA
FOIAengine: Media Requests Signaled Issues for a “Party Drug” Going Mainstream With 153 clinical trials to assess whether the party drug known as Ecstasy can help patients suffering from Post Traumatic Stress Disorder, optimism was high earlier this summer among...
by John A. Jenkins | Oct 31, 2024 | FDA, FOIA, Law Firms, Litigation
FOIAengine: Hundreds of Requests About FDA’s Tobacco Regulation With cigarette makers battling for market dominance in a “smoke-free future,” legal and marketing battles are raging – and recent Freedom of Information Act requests may signal what’s coming next. Womble...
by John A. Jenkins | Oct 10, 2024 | FOIA, Politics
FOIAengine: How the Project 2025 Personnel Database Gets Built As the presidential election nears, we’ve been tracking the opposition-research strategies of both major parties. Last week, we examined recent Freedom of Information Act requests from the Democratic...
by John A. Jenkins | Oct 3, 2024 | FOIA, Politics
FOIAengine: Latest Requests About Vance Target More Companies The Democratic National Committee’s latest Freedom of Information Act requests reveal an expanded effort to dig up details about possible federal investigations into various companies associated with...
by John A. Jenkins | Sep 11, 2024 | FDA, FOIA, FTC, SEC
FOIAengine Explores the Widespread Use of “Neither Confirm Nor Deny” By John A. Jenkins We’re taking a look this week at a frequently used Freedom of Information Act exemption that isn’t mentioned anywhere in the statutory language. It’s known as “Glomar” among the...
